Incyte posts Phase 3 STOP-HS2 results for povorcitinib; registers INCB161734 Phase 1 studyNov 6Weekly roundup, 2 itemsINCB161734Incyte CorporationUpdated
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Incyte's radiolabeled INCB161734 mass balance study active, not recruitingOct 16Weekly roundup, 4 itemsINCA33890INCB161734
Incyte registers two Phase 1 PK studies of INCB161734, in renal and hepatic impairmentOct 2Weekly roundup, 2 itemsINCB161734Incyte CorporationUpdated
Incyte posts terminated Phase 1 KRASG12C combo results; registers new INCB161734 mass balance studySep 11Weekly roundup, 2 itemsadagrasibBristol Myers Squibb